Granted Patent B2

US 12,396,974 · App. 17/907,470 · Granted Aug 26, 2025

Inventor: Frank Borges Llosa (Fall Church, VA)

Assignee: KetoneAid

A61K31/22A61K31/047A61K31/19A61K31/23A61K31/375A61K31/706A61P31/14

Abstract

Claims (24)

1. A method of treating the symptoms of a viral infection caused by SARS-CoV-2 in a subject in need of thereof, comprising administering to the subject suffering from the symptoms of the viral infection, a therapeutically effective amount of the compound according to Formula I, or a composition comprising a therapeutically effective amount of the compound of Formula I

2. The method of claim 1 , wherein the compound of Formula I is administered as a composition comprising the compound of Formula I and a pharmaceutically acceptable carrier.

3. The method of claim 1 , wherein the administration is oral or intravenous administration.

4. The method of claim 3 , wherein administering the compound according to Formula I results in a blood ketone body concentration from about 0.1 mM to about 20 mM.

5. The method of claim 3 , wherein the blood ketone body concentration is about 1 mM to about 5 mM.

6. The method of claim 3 , wherein the compound according to Formula I is administered in a dose of about 0.08 g to about 8 g per kilogram of the subject's body weight.

7. The method of claim 4 , wherein the compound according to Formula I is administered to the subject in need thereof in a dose of 0.8 g/kg to about 1.5 g/kg based on the subject's body weight.

8. The method of claim 1 , wherein the method further comprises administering vitamin C where in the vitamin C is administered in a dose of about 1 g to about 100 g.

9. The method of claim 1 , wherein the method further comprises administering at least one of a 3-hydroxybutyric acid salt, 1,3-butanediol, ethyl hydroxybutyrate, or MCT oil.

10. The method of claim 9 , wherein the 3-hydroxybutyric acid salt is selected from the group consisting of sodium 3-hydroxybutanoate, magnesium 3-hydroxybutanoate, calcium 3-hydroxybutanoate, potassium 3-hydroxybutanoate, and combinations thereof.

11. The method of claim 9 , wherein the MCT oil is a MCT (C8) oil.

12. The method of claim 1 , wherein the method further comprises administering nicotinamide riboside.

13. The method of claim 1 , wherein the symptoms of Covid-19 are long-term symptoms.

14. The method of claim 13 , wherein the long-term symptoms are selected from the group consisting of fatigue, shortness of breath, cough, joint pain, chest pain, difficulty with thinking and concentration (brain fog), depression, muscle pain, headache, intermittent fever, fast-beating or pounding heart, heart palpitations, inflammation of the heart muscle, lung function abnormalities, acute kidney injury, rash, hair loss, smell and taste problems, sleep issues, difficulty with concentration, memory problems, anxiety, change of mood, and combinations thereof.

15. The method of claim 1 , wherein the method further comprises administering one or more of the following:

a) a 3-hydroxybutyric acid salt;

b) 1,3-butanediol;

c) MCT C8 oil; or

d) 3-hydroxybutyric acid; and

wherein the 3-hydroxybutyric acid salt is selected from the group consisting of sodium 3-hydroxybutanoate, magnesium 3-hydroxybutanoate, calcium 3-hydroxybutanoate, potassium 3-hydroxybutanoate, and combinations thereof.

16. The method of claim 1 , wherein the compound of Formula I is enantiomerically enriched to about 90%.

17. The method of claim 1 , wherein the compound of Formula I is enantiomerically enriched to about 99.99%.

18. The method of claim 1 , wherein the method further comprises administering (3S)-hydroxybutyl (3S)-hydroxybutanoate and wherein the (3S)-hydroxybutyl (3S)-hydroxybutanoate and the compound of Formula I are present in a ratio of 1:1.

19. A method of alleviating the symptoms associated with a cytokine storm and hyper-inflammation, in a SARS-CoV-2 subject in need of thereof, comprising administering to the subject a therapeutically effective amount of the compound according to Formula I

Continuity (2)

References Cited (116)